Neurocrine Biosciences (NBIX) Other Operating Expenses (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Other Operating Expenses for 16 consecutive years, with $28.6 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $28.6 million; the trailing twelve-month figure through Jun 2026 stood at $77.5 million (up 263.85% YoY), and the FY2025 full-year result was $69.5 million, up 49.46% from the prior year.
• Other Operating Expenses retreated to $28.6 million in Q1 2026 per NBIX's latest filing, from $34.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $152.4 million in Q1 2023 and bottomed at $4.6 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $22.1 million across 5 years, with a median of $11.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses tumbled 92.62% in 2022, then surged 3213.04% in 2023.
• Over 5 years, Other Operating Expenses stood at $7.7 million in 2022, then gained by 10.39% to $8.5 million in 2023, then surged by 44.71% to $12.3 million in 2024, then soared by 181.3% to $34.6 million in 2025, then retreated by 17.34% to $28.6 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $28.6 million, $34.6 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.